Cambridge Biotherapies™, a leader in advanced mental health treatments, proudly announces the introduction of Spravato™ (esketamine) nasal spray therapy at its Beverly location, with plans to expand to other centers in the coming months. This breakthrough treatment offers rapid relief for patients suffering from treatment-resistant depression and is covered by most insurance companies

Personalized and Affordable Care

Cambridge Biotherapies is committed to tailoring treatments to meet each patient's unique needs. Spravato™ is administered under the careful supervision of healthcare professionals in a supportive and comfortable environment. Additionally, Spravato™ is covered by most insurance providers, making it a more accessible option compared to IV ketamine therapy.

Revolutionizing Affordable Depression Treatment

Daniel Brenner, M.D., Founder and Medical Director of Cambridge Biotherapies, emphasized the transformative potential of this treatment: "Spravato™ represents a significant advancement in our ability to treat severe depression affordably. It's common to see remarkable improvements in patients who previously had few options. We are thrilled to offer this life-changing therapy to our community."

Comprehensive Support at Every Step

Patients start their treatment journey with a thorough evaluation to determine eligibility and set therapeutic goals. The treatment involves self-administration of the nasal spray in a controlled clinical setting, followed by a two-hour monitoring period to ensure safety and effectiveness. Ongoing support and follow-up appointments help integrate the therapeutic benefits into daily life.

Expanding Access Across Massachusetts

Cambridge Biotherapies offers Spravato™ therapy in its Beverly & Cambridge locations and will extend this service to its Amherstlocation by early Fall 2024. Each center is staffed by specialists trained in the compassionate administration of Spravato™, ensuring patients receive the highest level of care.